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Abstract: Diseases such as myocardial infarction, ischaemic stroke, peripheral vascular disease
and venous thromboembolism are major contributors to morbidity and mortality. Procoagulant,
anticoagulant and fibrinolytic pathways are finely regulated in healthy individuals and dysregulated
procoagulant, anticoagulant and fibrinolytic pathways lead to arterial and venous thrombosis. In this
review article, we discuss the (patho)physiological role and laboratory assessment of fibrin, factor
XIII and endogenous fibrinolysis, which are key players in the terminal phase of the coagulation
cascade and fibrinolysis. Finally, we present the most up-to-date evidence for their involvement in
various disease states and assessment of cardiovascular risk.
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1. Introduction
Arterial thrombosis, especially in the context of myocardial infarction (MI), is most
commonly attributable to atheromatous plaque disruption and contact of procoagulant
substrate (subendothelial cells, tissue factor, collagen) with blood, leading to platelet
activation, aggregation and formation of an occlusive platelet-rich clot [1]. On the other
hand, venous thrombosis is most likely initiated by the interaction between dysfunctional—
but intact—endothelium expressing cell adhesion molecules and plasma hypercoagulability
combined with reduced blood flow, which subsequently leads to the formation of a red
blood cell (RBC)-rich thrombus [2]. Fibrin clot formation is the ultimate common event in
the coagulation cascade leading to thrombus formation, and there is emerging evidence
that the structure and properties of these clots may determine the outcome and persistence
of the thrombus [3]. Endogenous fibrinolysis is an important physiological countermeasure
against development and lasting arterial or venous thrombosis, and the dysfunctional
fibrinolytic process leads to both acute thrombosis and a chronic thromboembolic disease
process. Furthermore, the clot-stabilising effect of factor XIII (FXIII), which is found in cells
and plasma, is thought to contribute to pathological thrombosis. In this review, we present
the (patho)physiological role of fibrin and FXIII, which play a pivotal role in the terminal
phase of the coagulation cascade as well as the role of impaired endogenous fibrinolysis in
pathological thrombus formation. Finally, we summarize the currently available evidence
for the involvement of these in arterial and venous thrombotic events in various diseases
as well as their value in predicting future cardiovascular risk.
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1.1. Physiological Role of Fibrin
Fibrinogen is the product of three genes clustered on chromosome 4 [4], namely FGA,
FGB and FGG, each of which specifies the primary structure of one of its 3 polypeptide
chains Aa, Bβ and γ, respectively [5,6]. Fibrinogen is primarily synthesized in the liver at
a rate of 1.7–5 g/day [7]; however, its expression is strongly upregulated in response to
inflammation [6]. Approximately three-quarters of fibrinogen in humans is present in the
plasma, at concentrations between 1.5–3.0 mg/mL, but it can also be found in platelets,
lymph and interstitial fluid [8].
Fibrinogen is converted to fibrin during the final stages of the coagulation cascade.
The trigger for this conversion is the thrombin-mediated catalytic cleavage of fibrinogen
into fibrin. Thrombin cleaves N-terminal fibrinopeptides from the Aa- and Bβ-chains and
produces fibrin monomers that further polymerize into fibrin fibers [9]. This results in a
drastic change in solubility, which causes the polymerization, aggregation and branching
of molecules and, ultimately, the formation of insoluble fibrin fibers [3], which give rise
to the fibrin meshwork that is essential for the mechanical stability of a newly formed
clot [10–14]. To further stabilize the clot against proteolytic and mechanical insults, the
emerging fibrin fibers are covalently crosslinked by the activated form of factor XIII (FXIIIa),
a plasma transglutaminase, which is activated by thrombin in the presence of calcium
(Ca2+) [8]. Before cross-linking, the fibrin polymerization is reversible [15]; however, after
cross-linking, polymerization becomes irreversible. This ultimately leads to the formation
of a rigid but simultaneously elastic structure that is capable of withstanding mechanical
stress and is less susceptible to proteolytic disruption [3]. From a purely mechanistic point
of view, numerous studies [16,17] have shown that the fibrin network structure in a clot
is an important determinant of the viscoelastic properties of the clot and can significantly
influence its susceptibility to lysis. All of these parameters are heavily dependent on the
kinetics of fibrin polymerization. Thrombin concentration at the time of gelation has a
profound effect on fibrin clot structure, an effect previously demonstrated in vitro [18].
Clots formed at low thrombin concentrations are coarse and are composed of thick fibrin
fibers, which are highly susceptible to fibrinolysis [19]. On the other hand, the presence
of high thrombin concentration leads to formation of dense clots with thin fibers that are
highly branched and relatively resistant to fibrinolysis [18–22].
A recent proteomic study [23] has identified at least 48 proteins that are incorporated
by cross-linking into the growing plasma clot by FXIII. For the purposes of this review,
the most important ones appear to be a2-antiplasmin (A2AP) [24], plasminogen activator
inhibitor-1 (PAI-1) [24], plasminogen activator inhibitor-2 (PAI-2) [25,26], thrombin acti-
vatable fibrinolysis inhibitor (TAFI) and complement C3 [27], as they act as regulators of
fibrinolytic activity (see the relevant section below). Furthermore, clot quality is influenced
by cells and cell-derived components that are present at the site of injury, such as RBCs,
neutrophils and neutrophil extracellular traps [28–35].
Once a clot is formed, the fibrinolytic system is also activated, a process predominantly
regulated by the tissue plasminogen activator (t-PA)-mediated conversion of plasminogen
to plasmin. Fibrin serves as both a co-activator and a substrate for plasmin, which is
physiologically relevant, as it restricts fibrinolytic activity to the location of the formed
clot. This is a crucial step in achieving a dynamic equilibrium between clot formation and
lysis and to prevent uncontrolled clot propagation [3]. The effectiveness of the fibrinolytic
process depends both on the regulation of fibrinolytic enzyme activity, as well as the
physical characteristics of the fibrin network itself, such as fiber diameter, pore size, and
extent of branching. Weisel et al. [36] have demonstrated that, in general, clots composed
of thicker fibers appear to lyse faster compared to clots that are made up of thinner fibers.
Finally, platelet aggregation, clot retraction [37] and clot stretching [38], amongst others,
affect the rate of clot lysis.
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1.2. Assessment of Fibrin Clot Structure and Permeability
Since the properties of the fibrin fiber network in a clot can determine its mechanical
stability and resistance to the endogenous fibrinolysis, methods of assessment of the clot
structure have been developed to assess cardiovascular risk. Permeability of the fibrin clot
is a measure of how tightly packed the fibrin clot is. This can be assessed in citrated plasma,
mixed with thrombin to enable fibrin clot formation. The volume of buffer flowing through
the gel formed is subsequently used to calculate the clot permeation coefficient [39]. The
structure and properties of fibrin networks in clots can be further characterized using
scanning confocal microscopy and electron microscopy to determine parameters such as
fiber diameter, fiber length, fiber density, number of branching points and the size of pores
present in the mesh [8].
1.3. Involvement of Fibrin Clot Structure in Disease States
The association between fibrin clot structural characteristics and clinical pathologies
suggests that the fibrin network structure is indeed a critical determinant of hemostasis
and thrombosis. Numerous studies have demonstrated that dense networks of thinner and
more compact fibrin fibers are associated with increased thrombotic risk [40–42], whereas
more coarse networks comprising thicker and less compacted fibers are linked to increased
risk of bleeding and are more susceptible to fibrinolysis [18,22,40–44]. Growing evidence
suggests the idea that abnormal fibrin clot characteristics (such as permeation, turbidity,
compaction and lysis assays) may represent a novel risk factor for arterial and venous
thromboembolism (VTE) [45].
There are two recognised types of inherited fibrinogen disorders. Type I (which refers
to reduced quantity of fibrinogen) includes afibrinogenemia (plasma levels < 0.1 g/L) and
hypofibrinogenemia (plasma levels 0.1–1.5 g/L). Type II (which refers to a qualitative fib-
rinogen abnormality), also known as dysfibrinogenemia, describes a state of normal fibrino-
gen levels with low functional activity [46]. Interestingly, inherited fibrinogen disorders con-
fer both an increased bleeding risk and an increased risk of thromboembolic complications.
Altered clot structure in the context of disease was first observed in individuals
with advanced coronary artery disease (CAD) [47]. Dense fibrin fiber networks, which
were ~30% less permeable, were demonstrated in young (<45 years) male subjects [47,48].
Furthermore, patients aged < 50 years after a first MI had longer clot lysis, which was asso-
ciated with increased body mass index, blood pressure and C reactive protein [49]. Similar
but milder alterations in fibrin structure were reported by Mills et al. [41] in first-degree
healthy relatives of patients with premature CAD, suggesting a possible inherited predis-
position to altered fibrin network structure and disease. Collet et al. [50] demonstrated
that fibrin clot architecture was similarly altered in young survivors of MI, exhibiting
increased stiffness, shorter fibrin fibers and hypofibrinolysis. These findings were extended
to older individuals with advanced CAD, who had increased fiber density and resistance to
fibrinolysis compared to age-matched controls [51]. Reduced clot permeability, lysis time
(LT) and turbidity, attributed to more tightly packed and less porous fibrin networks, have
also been associated with significant complications of CAD, namely stent thrombosis and
no-reflow phenomenon [52]. Finally, reduced fibrin clot permeability and susceptibility to
lysis has also been observed in patients with a history of the no-reflow phenomenon after
acute MI [53].
Similar abnormal fibrin clot properties to those encountered in acute MI patients
have also been documented in patients during the acute phase of ischaemic stroke [54,55],
suggesting that reduced clot permeability and hypofibrinolysis contribute to the mechanism
of thrombosis. More importantly, in a study performed by Rooth et al. [56], the changes
observed during the acute phase of ischaemic stroke persist beyond 60 days from the index
event, suggesting that impaired fibrinolysis is a persistent characteristic in these patients.
Individuals with acute ischaemic stroke and concomitant CAD exhibited prolonged clot
lysis compared to controls without CAD history. Fibrin clot compaction was correlated with
a neurological deficit on both admission and discharge of subjects with acute ischaemic
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stroke [55]. More compact plasma clots (and thus more resistant to fibrinolysis) were
generated from plasma samples of individuals with cryptogenic stroke between 3 and
9 months earlier [57]. It should, however, be noted that ischaemic stroke is a rather
heterogeneous pathology, and it is not clear whether all types of ischaemic strokes share
the same underlying fibrin network properties.
Peripheral arterial disease (PAD) is another vascular condition where denser fibrin
clots with reduced permeability and susceptibility to lysis have been observed [47,58].
Worse clinical outcomes, namely increased risk of thromboembolism and further pro-
gression of PAD, were associated with the adverse clot phenotype. Altered fibrin clot
structure, in the form of poor permeability, increased rigidity/fiber thickness and resistance
to fibrinolysis was observed in 34 young individuals with intermittent claudication due to
PAD [59]. Hypofibrinolysis was also identified as a risk factor (2.3-fold increase in OR) for
arterial thrombosis at a young age in a study by Guimaraes et al. [60]. Additionally, altered
fibrin clot architecture and function was observed in healthy first-degree relatives of PAD
patients [61]. Patients with PAD, abdominal aortic aneurysm and end-stage renal failure
have been shown to have increased fibrinogen levels [62–64]. It is, however, notewor-
thy that fibrinogen levels appear to be of limited value in individualised risk assessment
of these patients [62]. It is unclear whether the observed fibrin clot abnormalities are a
biomarker of an underlying pathophysiological mechanism or a causative in the disease
etiology [65].
With regards to VTE, reduced fibrinolytic potential has been demonstrated in patients
following their first deep vein thrombosis (DVT) episode [66] and is a predictor of recurrent
VTE including pulmonary embolism [67]. In those patients, clot LT above the 90th percentile
was associated with a 2-fold increase in DVT risk. Idiopathic VTE patients, as well as their
asymptomatic first-degree relatives, were found to have lower clot permeability, lower
compaction and prolonged clot LT compared to controls, with those changes being more
pronounced in patient subjects. Interestingly, fibrin clot samples obtained from pulmonary
embolism patients were more permeable, more susceptible to lysis and less compact
compared to those of DVT patients [40]. It is unclear whether VTE patients with risk
factors such as trauma, surgery, known thrombophilia or cancer exhibit the same fibrin clot
property characteristics, as these were excluded from the above study.
Another group of patients in whom reduced fibrin clot permeability and resistance to
fibrinolysis has been documented is those with end-stage renal disease [68,69]. Purified
fibrinogen samples obtained from individuals on chronic haemodialysis showed evidence
of glycosylation and guanidinylation. Compared to healthy controls, fibrin clots with
the above biochemical alternations have been shown to have significantly thinner, more
compact and denser fibrin fiber networks [70]. Furthermore, the presence of denser fibrin
networks was independently associated with higher mortality. During a 3-year follow-up,
clots made from baseline plasma obtained from long-term hemodialysis patients who
died of cardiovascular causes were significantly less permeable and less susceptible to
lysis, compared to clots formed from controls without cardiovascular disease, indicating
a possible link between altered fibrin properties and worse outcome patients with renal
failure [71].
Prospective studies are needed to further elucidate whether fibrin clot parameters
can reliably predict individuals at an increased risk of thromboembolic events (arterial or
venous), both in the general population as well as in subjects with established disease.
1.4. Physiological Role of FXIII
FXIII is involved in the final part of the common coagulation pathway. Its discovery
can be traced back to 1948 when Laki and Lorand [72] first identified a serum factor that
made fibrin clots insoluble in concentrated urea solution, resulting in the term “protein-
fibrin-stabilizing factor”. It was later purified in 1961 by Lowey et al., who also reported its
enzymatic activity. In the same year, Duckert et al. [73] realised its clinical importance when
they published on a pediatric patient with severe bleeding diathesis, impaired wound
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healing and abnormal scar formation, in what probably appears to be the first documented
case of FXIII deficiency.
FXIII is a member of the transglutaminase family and is found in both cellular and
plasma fractions. It consists of subunits A (catalytic) and B (non-catalytic). The A subunit
consists of a sandwich domain, a catalytic domain, an activation peptide (AP) and two
barrel domains. The B subunit’s main defining molecular characteristic is the repetitive
ten sushi domain. The cellular form of FXIII is found in multiple cell types, including
megakaryocytes, platelets (alpha granules) [74], monocytes and osteoblasts [9]. The cellular
form consists of two identical FXIII-A subunits, which exist as a homodimer. Most platelet
FXIII is derived from megakaryocytes during platelet production, but platelets may also
uptake a small fraction of their FXIII from plasma [9], as well as translate FXIII messenger
ribonucleic acid de novo [75]. The plasma form exists as a heterotetramer (FXIII-A2B2) com-
posed of two FXIII-A and 2 FXIII-B subunits and circulates in complex with fibrinogen [76].
Both plasma and platelet FXIII forms are believed to contribute to blood coagulation via
means of fibrin clot stabilisation. During its activation, thrombin catalyzes the cleavage of
the AP from the FXIII-A subunit [77,78]. Subsequently, (Ca2+) promotes the dissociation of
the A and B subunits, and the FXIII-A becomes an active transglutaminase mediating the
fibrin cross-linking and clot stabilisation [79]. FXIII binding to fibrin(ogen) facilitates the
dissociation of the B subunits [80–82], essentially ascribing fibrin(ogen) with an important
regulatory role in FXIII activation. Finally, it should be noted that cellular FXIII can also
be activated without cleavage of the AP. Cellular FXIII can be proteolytically activated by
thrombin and the intracellular (Ca2+)-sensitive protease calpain in vitro [83]. When, how-
ever, FXIII activation is mediated by AP cleavage, the AP is released into circulation [78,84]
and has been used as a biomarker of acute ischaemic stroke [85].
Once activated, FXIII facilitates the cross-linking of fibrin fibers, stabilizing the in-
soluble clot against dislodgement by high shear stress [86]. Rather interestingly, this
cross-linking has only a minor effect (~12%) on fibrin network density [20,87–89]. However,
it substantially alters the structure of individual fibrin fibers by promoting protofibril
coupling within the fiber itself [90], which causes fiber compaction. This has two main
effects: firstly, it significantly increases the elastic modulus of individual fibers [91–93]
(fiber stiffening), as well as the whole clot network [94], making fibers more resistant to
deformation under low strain [90]. Secondly, it decreases the size of the pores within
individual fibers, with potentially profound effects on the ability of fibrinolytic molecules
(such as t-PA), to diffuse within the clot [9].
Crucially, beyond the fibrin fiber cross-linking described above, at least some of the
anti-fibrinolytic action of FXIII is mediated by its ability to crosslink antifibrinolytic proteins
within the fibrin clot itself (Figure 1). These include A2AP [95,96], TAFI [97] and PAI-1 [98].
In particular, cross-linked A2AP, which is essential for the inhibition of fibrinolysis, remains
fully active and protects the formed clot from spontaneous fibrinolysis by t-PA-induced
plasminogen activation on the surface of fibrin fibers [99].
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Major regulators of fibrinolysis include a2-antiplasmin (A2AP), thrombin-activatable fibrinolysis inhibitor (TAFI) and 
plasminogen activator inhibitor (PAI-1). 
Finally, there are data suggesting that FXIII-mediated cross-linking also has a signif-
icant effect on thrombus RBC content. Wolberg et al. [100] have demonstrated that FXIIIa 
promotes red blood cell retention in contracting clots by crosslinking fibrin a-chains. Sim-
ilarly, Aleman et al. [101] have observed reduced RBC retention in contracted human 
whole blood clots, in the presence of FXIII inhibitors or reduced concentration of FXIII. 
Since clot contraction packs and deforms RBC within the clot, it has the potential to de-
crease permeability [30], rendering it a major determinant of clot composition. 
Given the above, it is clear that FXIII exerts a multitude of effects on clot structure 
and function. These are not limited solely to the simplistic mechanical cross-linking of 
individual fibrin fibers within the clot network but extend beyond this, affecting the bio-
chemical and cellular composition of the clot itself, conferring additional resistance to fi-
brinolysis. There is growing evidence from epidemiological, biochemical and animal 
model studies suggesting that FXIII is indeed an important determinant of thrombus com-
position and stability [9]. 
Beyond its critical role in the coagulation cascade, other numerous “novel” functions 
of FXIII (especially of its cellular form) have been identified and are under investigation. 
It plays a role in extracellular matrix deposition and osteoblast differentiation, with inhi-
bition of FXIIIa resulting in reduced fibronectin and collagen matrix assembly and de-
creased bone mineralization [102]. Furthermore, FXIII has been reported to be present in 
adipocytes, where it acts as an antagonist for adipocyte differentiation and lipid accumu-
lation [103]. In addition, FXIIII has been identified as having an important function in 
wound healing and tissue repair by enabling cross-linking of proteins in the extracellular 
matrix and promoting cellular signaling between leukocytes and endothelial cells, which 
enhances cell motility, proliferation, angiogenesis and contributes to immune processes 
[104,105]. Interaction with the extracellular matrix probably also explains why FXIII is es-
sential for maintaining pregnancy [74], as evidenced by the fact that women with FXIII 
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Figure 1. Thrombus formation and stabilisation: Coagulation factor XIII (FXIII) crosslinks fibrin fibers and stabilises the
insoluble clot against dislodgement by high shear stress. It also decreases the size of the fibrin pores, reducing the ability of
fibrinolytic molecules (such as tissue plasminogen activator (t-PA)) to diffuse within the clot. In addition, FXIII mediates
the crosslinking of various antifibrinolytic proteins within the fibrin clot structure itself, further inhibiting clot dissolution.
Major regulators of fibrinolysis include a2-antiplasmin (A2AP), thrombin-activatable fibrinolysis inhibitor (TAFI) and
plasminogen activator inhibitor (PAI-1).
Finally, there are data suggesting that FXIII-mediated cross-linking also has a signifi-
cant effect on thrombus RBC content. Wolberg et al. [100] have demonstrated that FXIIIa
promotes red blood cell retention in contracting clots by crosslinking fibrin a-chains. Simi-
larly, Aleman et al. [101] have observed reduced RBC retention in contracted human whole
blood clots, in the presence of FXIII inhibitors or reduced concentration of FXIII. Since
clot contraction packs and deforms RBC within the clot, it has the potential to decrease
permeability [30], rendering it a major determinant of clot composition.
Given the above, it is clear that FXIII exerts a multitude of effects on clot structure
and function. These are not limited solely to the simplistic mechanical cross-linking of
individual fibrin fibers within the clot network but extend beyond this, affecting the
biochemical and cellular composition of the clot itself, conferring additional resistance to
fibrinolysis. There is growing evidence from epidemiological, biochemical and animal
model studies suggesting that FXIII is indeed an important determinant of thrombus
composition and stability [9].
Beyond its critical role in the coagulation cascade, other numerous “novel” functions
of FXIII (especially of its cellular form) have been identified and are under investigation. It
plays a role in extracellular matrix deposition and osteoblast differentiation, with inhibition
of FXIIIa resulting in reduced fibronectin and collagen matrix assembly and decreased bone
mineralization [102]. Furthermore, FXIII has been reported to be present in adipocytes,
where it acts as an antagonist for adipocyte differentiation and lipid accumulation [103].
In addition, FXIIII has been identified as having an important function in wound healing
and tissue repair by enabling cross-linking of proteins in the extracellular matrix and
promoting cellular signaling between leukocytes and endothelial cells, which enhances
cell motility, proliferation, angiogenesis and contributes to immune processes [104,105].
Interaction with the extracellular matrix probably also explains why FXIII is essential for
maintaining pregna cy [74], s evidenced by the fact that women with FXIII deficiency
suffer from recurrent spontaneous abortions e rly in the course of pregnancy [106]. Si e
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these functions of FXIIII are beyond the scope of this review article, the reader is encouraged
to refer to the excellent articles above for further details.
2. Measurement of FXIII
Unlike other coagulation factors, factor XIII level does not influence the routine
coagulation screen tests such as prothrombin time or activated partial thromboplastin time.
Therefore, high clinical suspicion and prompt investigations with specific tests to detect
factor XIII level are required in clinical practice. There are several available assays for
performing quantitative and qualitative assessment of FXIII levels and activity, including
testing for the presence of FXIII inhibitors. These can broadly be categorised as follows.
2.1. FXIII Activity Assays
2.1.1. Clot Solubility Test
This assay evaluates the stability of cross-linked fibrin. Clotting of citrated plasma
is initiated by the addition of (Ca2+) and/or thrombin. It is then exposed to a protein
denaturating agent (such as urea, acetic acid or momoacetic acid). The presence of cross-
linked fibrin can be detected as it is more stable (and thus more resistant to denaturation),
compared to un-crosslinked fibrin, which readily denatures and dissolves into solution.
This is a simple, cost-effective and simple-to-implement method. It is, however, able to
detect only severe FXIII deficiency.
2.1.2. Quantitative Activity Assays
These assays rely upon the two different activities of FXIII: The transglutaminase
activity and the isopeptidase activity. In short, the transglutaminase activity leads to
the release of an ammonia molecule. The isopeptidase activity is characterised by the
hydrolysis of isopeptide bonds.
I. Ammonia assays (the most commonly used in clinical laboratories) quantify the am-
monia released due to FXIII’s transglutaminase activity, utilising spectrophotometry.
This acts as an indirect measurement of transglutaminase activity and is used to
quantify overall FXIII activity.
II. Amine-incorporation assays also quantify FXIII’s transglutaminase activity by assess-
ing the isoamide bond formation, catalysed by FXIIIa. A labeled amine substrate,
such as 5-biotinamidopentylamine, is paired with a glutamine-containing protein,
such as casein. The activity of FXIIIa is quantified by measuring the residual unin-
corporated labeled amine. Importantly, amine incorporation assays may yield falsely
elevated FXIII activity levels in subjects with the common Val34Leu polymorphism,
which is present in ~25% of European Caucasians [107]. Thus, it is rarely used in the
clinical setting.
III. Isopeptidase assays measure the FXIIIa-dependent hydrolysis of γ:ε isopeptide bonds.
A FXIII substrate (A101) with a fluorophore and a fluorescent quencher linked by γ:ε
isopeptide bonds is formulated. The isopeptidase-dependent release of the quencher
unmasks A101 fluorescence which is detected by a spectrofluorometer, allowing for
dynamic measurement of FXIII enzyme activity.
3. FXIII Quantitative Antigen Assays
These assays measure FXIII-A2, FXIII-B2 and FXIII-A2 B2 complexes by latex antigen
immunoassay. They are used for the detection and classification of FXIII deficiencies, as
well as monitoring of response to therapy and are widely used in the UK (~40% of centers).
In particular, the HemosIL FXIII-A2 assay is approved for use by the United States Food
and Drug Administration.
4. FXIII Genotyping
The encoding genes of FXIII-A (F13A1) and FXIII-B (F13B) have been mapped in the
human genome and are located in positions 6p24–25 and 1q31–32.1, respectively. More
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than 153 mutations have so far been described. Over 95% of FXIII deficiency cases are
due to FXIII-A deficiency [108,109]. The large number of mutations and polymorphisms
of the FXIII A and B genes that have been described are comprehensively presented by
Biswas et al. [110].
A more detailed overview of the laboratory assessment of FXIII and the standard algo-
rithm endorsed by the Scientific and Standardization Committee of the International Society
of Thrombosis and Haemostasis for the diagnosis and classification of FXIII deficiency has
previously been reviewed in detail by Dorgalaleh et al. [111] and Durda et al. [86].
4.1. Involvement of FXIII in Disease States
Congenital FXIII deficiency is a rare bleeding disorder that is inherited in an autosomal
recessive pattern. It usually presents in the neonatal period and can result in severe
bleeding, most commonly manifesting in umbilical cord bleeding (80%) [112] or intracranial
hemorrhage (30%) in the severe form of the disease. Post-traumatic intracranial hemorrhage
is often the first sign of mild to moderate FXIII deficiency in older children [113]. Other
presentations include deep and superficial hematomas and prolonged bleeding after trauma
or surgery in this age group [114]. Women with congenital FXIII deficiency suffer significant
bleeding complications. Menorrhagia is a common symptom. Pregnancies in women with
FXIII deficiency have a significant risk of miscarriage, placental abruption and post-partum
hemorrhage if not on prophylaxis treatment [115].
Contrary to the common manifestations of bleeding, FXIII has been implicated as a
contributing factor to arterial and venous thrombosis. Numerous studies have examined
the contribution of FXIII in arterial and venous thrombosis [116–118] mostly involving the
Val34Leu polymorphism, which causes accelerated release of the FXIII AP and results in
earlier activation and thus faster fibrin cross-linking in vitro [119,120].
Meta-analysis of early studies performed to evaluate the effect of Val34Leu polymor-
phism suggests that the presence of the Val34Leu polymorphism offers modest protection
against CAD (odds ratio (OR) 0.81, 95% confidence interval (CI) 0.70–0.92) and VTE (OR
0.85, 95% CI 0.77–0.95) [121].
In a large prospective study (EPIC-Norfolk) evaluating the risk of CAD in association
with the Val34Leu variant and fibrinogen levels, it was found that Val34Leu homozygotes
in the lowest tertile of fibrinogen concentration had increased risk of CAD, whereas
individuals in the highest tertile showed a trend towards reduced risk of CAD [122].
Similarly, in a high-risk Hungarian population, the presence of the Val34Leu allele in
those with elevated fibrinogen levels was associated with protection against MI [123]. The
presence of the allele, however, did not appear to confer any MI risk reduction in the
general population. The proposed mechanism for the effects observed is that the highly
active Val34Leu variant of FXIII in the presence of high fibrinogen concentrations gives
rise to clots with thicker fibers, which have increased permeability and thus are more
susceptible to fibrinolysis [124].
A meta-analysis of 36 studies, performed by Jung et al. in 2017 [125] found that
FXIII Val34Leu polymorphism was associated with CAD risk, especially MI, but not with
CAD without MI. Of note, the age and sex of the individuals did not appear to affect
the relationship between the presence of the polymorphism and CAD risk. In a study of
113 patients [126] who planned to undergo elective coronary artery bypass grafting, the
FXIII Val34Leu allele was associated with decreased fibrin clot permeability and efficiency
of lysis ex vivo. In 474 patients with DVT enrolled in the Leiden Thrombophilia Study,
Val34Leu homozygosity in the context of high fibrinogen levels was found to confer
vascular protection to both sexes, especially in those individuals over 45 years of age (OR
0.4, 95% CI 0.2–1.0) [127]. Another polymorphism of the FXIII-B subunit, His95Arg, was
associated with mildly increased risk of venous thrombosis in Dutch Caucasians (OR 1.5,
95% CI 1.1–2.0) [128].
Other polymorphisms include the FXIII-A Tyr204Phe, which has been shown to be
associated with a 9–11-fold increase in risk for MI and ischaemic stroke in a cohort of
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young Dutch women [129,130]; however, a similar association has not been demonstrated
in a Brazilian population [131]. Mezei et al. [132] demonstrated that FXIII activity and
FXIII-A2B2 antigen levels were significantly higher in females with VTE history compared
to controls. FXIII-B levels were significantly lower in males with VTE than in the control
group, highlighting an interesting sex-specific difference. Interestingly, neither p.His95Arg
nor the intron K C > G polymorphism exerted any significant effect on the risk of VTE.
Inhibition of FXIIIa may be an avenue to achieve anticoagulation with limited bleeding
risk with a few FXIIIa inhibitors currently under development, including small molecules
and polypeptides. Of these, development of the hexapeptide-like ZED3197 and the polypep-
tide tridegin appear to be the most advanced. None are currently approved for use, and
clinical trials are pending.
4.2. Physiological Role of Fibrinolysis
Fibrinolysis is the process of fibrin degradation that results in clot dissolution. The
process involves the conversion of plasminogen to plasmin by tissue plasminogen acti-
vator (t-PA) or urokinase-type plasminogen activator (u-PA), which then degrades fibrin
to fibrin degradation products, including D-dimer. The maintenance of an equilibrium
between coagulation and fibrinolysis plays a vital role in the maintenance of homeostasis
in order to prevent either uncontrolled thrombosis (defined as pathological formation
of an intravascular clot in the absence of injury) or abnormal bleeding with potentially
fatal consequences. If thrombus formation were to continue unchecked, it would lead
to complete occlusion of the vessel in question and complete loss of blood flow down-
stream, resulting in catastrophic tissue damage, as is the case in acute MI, ischaemic stroke
and acute peripheral vascular occlusion [133]. On the other hand, hyperfibrinolysis can
lead to uncontrolled bleeding, as in the case of disseminated intravascular coagulation.
Endogenous fibrinolysis (also known as spontaneous fibrinolysis) is therefore the body’s
physiological countermeasure against lasting arterial or venous thrombosis.
The hallmark of the activation of the fibrinolytic system is the conversion of plas-
minogen into its active form, plasmin. Plasmin subsequently degrades insoluble fibrin
fibers into soluble fibrin degradation products [134]. There are two physiological molecules
that are capable of catalysing the conversion of plasminogen into plasmin. These are t-PA
and urokinase-type plasminogen activator (u-PA) [135]. In the absence of fibrin, t-PA is
a relatively poor plasminogen activator; however, its enzymatic activity is increased by
orders of magnitude in the presence of fibrin, making it a fibrin-specific agent [27].
In healthy individuals, fibrinolytic activity regulation occurs at the level of plasmino-
gen activation, mainly through the action of PAI-1 and PAI-2, which are effective against
both t-PA and u-PA [134,136]. PAI-1 is the most abundant one and is produced by platelets
and endothelial cells, whereas PAI-2 is produced by the placenta and is only detectable at
appreciable levels during pregnancy [136,137].
Downregulation of the fibrinolytic system can also occur at the level of plasmin by
the antagonizing effect exerted through A2AP [138]. A2AP forms a complex with plasmin,
inhibits absorption of plasminogen onto fibrin and cross-links with FXIIIa to make fibrin
more resistant to the effects of plasmin [133].
Another molecule capable of inhibiting the degradation of fibrin is TAFI [139]. It is ac-
tivated following thrombin-mediated cleavage and acts by means of reducing plasminogen
binding to partially degraded fibrin, as evidenced by increased LT [134,140]. The action of
TAFI is greatly enhanced by thrombomodulin [141,142].
Finally, lipoprotein(a), Lp(a), is yet another modulator of fibrinolysis. Its molecular
structure resembles that of plasminogen and it competitively binds to fibrin to exert its
anti-fibrinolytic effect. In addition, it can also increase the rate of PAI-1 production by the
endothelium, further reducing plasmin levels [143].
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5. Measurement of Fibrinolysis
Although the physiological importance of endogenous fibrinolysis has been appreci-
ated for decades, its measurement has been a challenge. There is no standard laboratory
test to assess the fibrinolysis, and methods available are outlined below.
5.1. Assessment of Level/Activity of Individual Molecules (Factors) Regulating Fibrinolysis
As previously discussed, fibrinolysis involves a multitude of different molecules
(plasmin, t-PA, urokinase, PAI-1/-2, A2AP, TAFI etc.) interacting with each other in a
highly dynamic process. These individual molecules are produced in different locations,
their individual concentrations may be augmented locally due to continuous flow of blood,
and the magnitude of their respective effects in the fibrinolytic process as a whole can be
challenging to accurately assess. As a result, measuring the level and/or the activity of
individual molecules participating in the fibrinolysis pathway has so far been disappointing
in producing prognostic data [144], with the exception of PAI-1, which has been shown
to be a predictor of disease severity and all-cause mortality in sepsis [145]. This notion
is exemplified by the assessment of t-PA. Studies have shown that high levels are in
fact associated with greater cardiovascular risk, despite the physiological role of t-PA as
potentiator of fibrinolysis [146,147].
5.2. Global Assessment of Fibrinolysis
Euglobulin clot lysis. This method, citrated plasma is acidified and incubated to form
a precipitate to which (Ca2+) is then added to initiate clotting. The time taken to lyse the
clot is measured. This is an outdated technique that has largely been replaced by newer
methods described below.
5.2.1. Plasma Clot Lysis Time (LT)
In this method, citrated platelet-poor plasma is obtained via centrifugation. The
clotting process is initiated by the addition of (Ca2+) and a coagulation activator such as
thrombin or recombinant tissue factor into the mixture. Use of recombinant tissue factor
may produce more physiologically relevant results, since it takes into consideration the
patients’ thrombin generation capacity [148]. Fibrinolysis is initiated by the addition of
plasminogen activator. The mixture is then left static, and changes in turbidity are used to
estimate thrombus formation and lysis. Fibrinolysis is defined as the time taken for the
maximum turbidity to drop by 50%.
Both the above methods of fibrinolysis assessment require the external addition of
activators of coagulation and fibrinolysis and are thus not accurate reflections of endoge-
nous processes taking place in vivo. Another major limitation arises from the fact that they
both fail to incorporate into their assessment the effect of any of the cellular components of
whole blood. Finally, as they are both static tests, they fail to account for any effects that
blood flow and shear stress (on platelets) have on both coagulation and fibrinolysis.
5.2.2. Global Thrombosis Test (GTT)
(Thromboquest Ltd., London, United Kingdom). This method measures coagulation
and endogenous fibrinolysis in whole non-anticoagulated blood, most closely resembling
physiological conditions in vivo. In this method, blood is subjected to flow under high
shear stress, which results in platelet activation and aggregation. This leads to the arrest
of blood flow due to the formation of an occlusive thrombus. The time taken to form an
occlusive thrombus is termed occlusion time (OT) and is a marker of platelet reactivity and
platelet thrombus formation. Due to subsequent endogenous fibrinolysis, the blood flow
is eventually restored, following lysis of the initial occlusive thrombus. The time taken
for the restart of flow is termed lysis time (LT) and is reflective of endogenous fibrinolysis
activity. This method better mimics the conditions of clot formation (high shear stress),
which are typically encountered in the arterial tree [144].
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Viscoelastic methods include thromboelastography (TEG) (Haemoscope Corporation,
Niles, Illinois) and the rotational thromboelastometry (ROTEM) (Tem International GmbH,
Munich, Germany). Both tests provide information on clot formation, propagation, strength,
stabilization and dissolution and are therefore able to provide a global assessment of
coagulation and fibrinolysis. In TEG, whole or citrated blood can be used. The sample
of blood is placed in a disposable cup, which undergoes constant rotational movement
mimicking a low flow state similar to that encountered in the venous tree. Coagulation
is activated by the addition of tissue factor or kaolin (for extrinsic and intrinsic pathways
respectively). A pin is suspended in the blood sample, and as coagulation starts and clot
formation is initiated, the varying forces exerted on the pin, as a result of viscoelasticity,
are measured and plotted. Various indices are measured, including, but not limited to,
the time (R) taken to form the initial clot and the clot strength (MA). Following that, the
degree of clot lysis is measured at 30 and 60 min, reflecting fibrinolytic activity [144]. The
main limitation of this technique is that it reflects static low flow thrombus formation,
reflective of venous, rather than arterial, thrombosis. Furthermore, standard protocols
(utilizing high tissue factor concentrations) are less sensitive in demonstrating clinically
relevant hypofibrinolysis and are only sensitive to pronounced hyperfibrinolysis. Modified
thromboelastometry protocols, with lower tissue factor concentrations and the addition of
tissue plasminogen activator, may be of value [149,150].
6. Involvement of Fibrinolysis in Disease States
Patients presenting with ST-segment elevation myocardial infarction (STEMI) who
achieve spontaneous reperfusion are believed to do so as a result of an effective endoge-
nous fibrinolysis. This is associated with more favourable clinical outcomes, such as lower
reinfarction rate, heart failure and overall lower mortality [151,152]. Impaired endogenous
fibrinolysis in the context of acute coronary syndrome (ACS) has been shown to be associ-
ated with an increased rate of major cardiovascular adverse events (MACE) at 1 year and
cardiovascular death. In a study of 300 patients presenting with ACS, impaired endogenous
fibrinolysis, defined as LT in excess of 3000 sec, as assessed by GTT, occurred in some 20%
of patients [153]. In a more recent study involving 496 patients presenting with STEMI,
impaired endogenous fibrinolysis assessed upon arrival to the catheterisation laboratory
was highly predictive of MI (HR 6.2, 95% CI 2.64–14.73; p < 0.001), MACE (HR: 9.1, 95% CI
5.29–15.75; p < 0.001) and cardiovascular death (HR 18.5, 95% CI 7.69–44.31; p < 0.001)
at 1 year [154]. Importantly, the association remained significant following adjustment
for baseline cardiovascular risk factors. The prognostic impact of impaired endogenous
fibrinolysis was also assessed in a sub-study of the PLATO study by Sumaya et al. [155].
This was performed by obtaining blood samples on discharge following hospitalisation for
ACS in 4354 patients. Assessment of fibrinolysis potential, as measured by clot LT (defined
as time to achieve 50% reduction in sample turbidity), correlated with cardiovascular death
and MI at 1 year, following adjustment for known cardiovascular risk factors (HR 1.17,
95% CI 1.05–1.31; p < 0.01).
Similar to patients with ACS, differences in endogenous fibrinolysis have also been
observed in acute ischaemic stroke populations. In a study of 335 individuals, out of
which 103 had an ischaemic stroke, clot LT was longer in patients than that in controls [60].
A study of 74 patients with ischaemic stroke, short CLT on admission to hospital was
predictive of favorable outcome at 3 months [156]. Similarly, Drabik et al. [157] showed
that CLT—in addition to the CHA2DS2-VASc score—was predictive of future events over
a median follow up period of 4.3 years in 236 patients with atrial fibrillation who were
treated with vitamin K antagonists. Taomoto et al. [158] compared 185 patients with acute
cerebral infarction with 195 healthy volunteers, two weeks following the index event. They
showed that the endogenous fibrinolytic activity in patients was significantly impaired
(longer LT) compared to healthy individuals (3159 ± 1549 s vs. 2231 ± 1223 s respectively),
despite antiplatelet medication. Prior to antiplatelet therapy initiation, the LT of patients
was prolonged even further.
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The thrombotic and thrombolytic status of 216 patients with ESRD on hemodialysis
was assessed by Sharma et al. [159] using the GTT. Impaired endogenous fibrinolysis
(defined as LT > 3000 sec) was strongly associated with MACE (HR 4.25, 95% CI 1.58–11.46,
p = 0.004), non-fatal MI and stroke (HR 14.28, 95% CI 1.86–109.90, p = 0.01), and peripheral
thrombosis (HR 9.08, 95% CI 2.08–39.75, p = 0.003). However, no association was found
between OT and MACE. Finally, LT has been shown to be significantly prolonged in male
habitual smokers compared to non-smokers by Suehiro et al. [160], suggesting attenuation
of spontaneous fibrinolytic activity due to smoking.
Two studies utilising viscoelastic methods in the assessment of endogenous fibrinoly-
sis in stroke have been unable to demonstrate any clinically relevant differences. ROTEM
was utilised in a study of 143 individuals with stroke [161] but did not reveal any significant
differences in coagulation and fibrinolysis parameters between patients and controls or to
associate fibrinolytic activity to stroke severity. In a study of 171 patients with ischaemic
stroke, before and after t-PA administration, TEG was unsuccessful in detecting responders
from non-responders to t-PA therapy [162]. These results might partially be attributed to
the limitations of standard viscoelastic protocols in detecting clinically relevant changes of
fibrinolytic capacity, as discussed at the end of the previous section.
Assessment of fibrinolytic factors in patients with stroke does appear to relate to
clinical outcomes. In 109 patients with ischaemic stroke, higher TAFI levels on admission
were associated with more severe National Institutes of Health Stroke scale and disabil-
ity in patients receiving or not receiving thrombolysis [163]. In another small study of
43 patients with acute ischaemic stroke treated with thrombolysis, an association was found
between higher PAI-1 levels on admission and angiographic failure of culprit cerebral artery
recanalisation [164].
Studies assessing fibrinolytic potential in venous thrombosis [66,165,166] have asso-
ciated prolonged clot LT with a two-fold increase in the prevalence of thrombotic events.
Hypofibrinolysis, as assessed by a plasma-based clot lysis assay, has been associated
with increased risk of a first venous or arterial event but not with recurrence of venous
thrombosis [167]. In addition, a study of 704 patients who had experienced unprovoked
VTE reported an association between clot LT (split into quartiles) and risk of future VTE
recurrence in women [168].
7. Conclusions
The equilibrium between coagulant and fibrinolytic pathways plays an important
role in regulating thrombosis and hemostasis. There is growing evidence to suggest that
mechanical and biochemical properties of the fibrin clot, the fibrinolysis-inhibitory effect
of FXIII and overall impairment of endogenous fibrinolysis all play a crucial role in the
dynamic process of clot formation and dissolution and contribute significantly to the
pathophysiology of cardiovascular events. Further studies are needed with clinically
relevant point-of-care global assays to assess the fibrinolytic function and the potential to
improve this to reduce cardiovascular risk.
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58. Undas, A.; Nowakowski, T.; Cieśla-Dul, M.; Sadowski, J. Abnormal plasma fibrin clot characteristics are associated with worse
clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis 2011, 215, 481–486.
[CrossRef]
59. Bhasin, N.; Parry, D.J.; Scott, D.J.A.; Ariëns, R.; Grant, P.J.; West, R.M. Regarding “Altered fibrin clot structure and function in
individuals with intermittent claudication. ” J. Vasc. Surg. 2009, 49, 1088–1089. [CrossRef]
60. Guimarães, A.H.C.; De Bruijne, E.L.E.; Lisman, T.; Dippel, D.W.J.; Deckers, J.W.; Poldermans, N.; Rijken, D.C.; Leebeek, F.W.
Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br. J. Haematol. 2009, 145, 115–120. [CrossRef]
61. Bhasin, N.; Ariëns, R.; West, R.M.; Parry, D.J.; Grant, P.J.; Scott, D.J.A. Altered fibrin clot structure and function in the healthy
first-degree relatives of subjects with intermittent claudication. J. Vasc. Surg. 2008, 48, 1497–1503. [CrossRef] [PubMed]
62. Bartlett, J.W.; De Stavola, B.; Meade, T.W. Assessing the contribution of fibrinogen in predicting risk of death in men with
peripheral arterial disease. J. Thromb. Haemost. 2009, 7, 270–276. [CrossRef] [PubMed]
63. Parry, D.J.; Al-Barjas, H.S.; Chappell, L.; Rashid, T.; Ariëns, R.A.S.; Scott, D.J.A. Haemostatic and fibrinolytic factors in men with a
small abdominal aortic aneurysm. Br. J. Surg. 2009, 96, 870–877. [CrossRef] [PubMed]
64. Chen, J.; Mohler, E.R., III; Xie, D.; Shlipak, M.G.; Townsend, R.R.; Appel, L.J.; Raj, D.S.; Ojo, A.O.; Schreiber, M.J.; Strauss,
L.F.; et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am. J. Cardiol. 2012, 110,
136–141. [CrossRef]
65. Kattula, S.; Byrnes, J.R.; Wolberg, A.S. Fibrinogen and Fibrin in Hemostasis and Thrombosis. Arterioscler. Thromb. Vasc. Biol. 2017,
37, e13–e21. [CrossRef]
66. Lisman, T.; de Groot, P.G.; Meijers, J.C.M.; Rosendaal, F.R. Reduced plasma fibrinolytic potential is a risk factor for venous
thrombosis. Blood 2005, 105, 1102–1105. [CrossRef]
67. Undas, A.; Natorska, J. Improving fibrinolysis in venous thromboembolism: Impact of fibrin structure. Expert Rev. Hematol. 2019,
12, 597–607. [CrossRef]
68. Sjøland, J.A.; Sidelmann, J.J.; Brabrand, M.; Pedersen, R.S.; Pedersen, J.H.; Esbensen, K.; Standeven, K.F.; Ariëns, R.A.; Gram, J.
Fibrin clot structure in patients with end-stage renal disease. Thromb. Haemost. 2007, 98, 339–345.
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